Complete Supplementation Stack for the Multi-Morbidity Case
Based on the integrated simulation (8 disease profiles + 2 deficiencies + contact dermatitis), here is the tiered, chronologically-ordered stack:
Tier 1 — Root Chokepoints (Start Day 0, Non-Negotiable)
Supplement Dose Timing Target Shunt Mechanism
* Sapropterin (BH4) 10–20 mg/kg/day (or 1000–2000 mg/day) AM, with food REDOX_BH4_LOCK (BH4_NOS/BH4_AAAH) Direct BH4 repletion → recouples NOS, restores AAAH (dopamine/serotonin/melatonin synthesis)
Methylcobalamin (B12) 2–5 mg sublingual daily AM BH4_METHYLATION_STRESS, KYNURENINE_FATIGUE_SHUNT Methylation support; lowers homocysteine → preserves BH4 from homocysteine competition
Folinic acid 800 mcg–2 mg/day AM BH4_METHYLATION_STRESS 1C cycle; NOT folic acid (blocks FRα)
Glycine 3–5 g/day (up to 10 g if tolerated) Divided doses, empty stomach GLYCINE_SINK_COMPETITION_T2D, REDOX_IMBALANCE Direct substrate for GSH, creatine, heme; raises plasma glycine >200 µM
N-Acetylcysteine (NAC) 1200–2400 mg/day (600 mg BID–TID) With meals GLUCOSE_TOXICITY_OXIDATIVE_STRESS, ELECTROPHILE_NUCLEOPHILE_ADDUCTION Glutathione precursor; competing nucleophile that binds electrophiles before skin proteins do
Rationale: These five agents hit all convergent nodes simultaneously. Without BH4, the NOS shunt remains uncoupled and peroxynitrite self-amplifies. Without glycine + NAC, the GSH pool cannot regenerate. Without B12 + folinic acid, methylation block deepens BH4 depletion.
Tier 2 — Gut Barrier & Histamine (Start Day 14–21)
Supplement Dose Timing Target Shunt Mechanism
L-Glutamine 5–10 g/day Empty stomach GUT_DYSBIOSIS_CROHNS, GUT_BARRIER_DISRUPTION Enterocyte fuel; tight junction repair (occludin, claudin)
Zinc (chelated) 30–50 mg elemental With food TRANSMURAL_INFLAMMATION, BASEMENT_MEMBRANE_PROTEOLYSIS MMP modulation; metallothionein induction; mucosal healing
Saccharomyces boulardii 250–500 mg/day (5–10 billion CFU) With meals GUT_DYSBIOSIS_CROHNS Anti-inflammatory probiotic; competitive exclusion of AIEC; raises secretory IgA
Quercetin 500–1000 mg/day (phytosome for absorption) Divided doses MAST_CELL_PRIMING_LOOP, MAST_CELL_DERMAL_BLISTERING_CASCADE Critical mast cell stabilizer; inhibits NLRP3; blocks B-cell proliferation
Vitamin C (ascorbate) 2–4 g/day (buffered or liposomal) Divided doses REDOX_BH4_LOCK, ELECTROPHILE_NUCLEOPHILE_ADDUCTION Reduces BH2→BH4; reduces oxidized electrophiles; cofactor for histamine degradation
Rationale: Gut barrier loss allows systemic access to bacterial LPS, food antigens, and histamine. MCAS amplifies every other shunt. Quercetin is the highest-priority agent in this tier — without mast cell stabilization, the histamine/tryptase cascade keeps the immune toggle locked.
Tier 3 — Mitochondrial & Metabolic (Start Day 30–45)
Supplement Dose Timing Target Shunt Mechanism
Alpha-Lipoic Acid (R-ALA) 300–600 mg/day Empty stomach MITOCHONDRIAL_FAILURE, GLUCOSE_TOXICITY_OXIDATIVE_STRESS Mitochondrial antioxidant; PDH cofactor; recycles GSH, vitamin C, vitamin E
CoQ10 (ubiquinol) 200–400 mg/day With fat MITOCHONDRIAL_FAILURE, REDOX_MITOCHONDRIAL_LOCK Complex I/III electron shuttle; bypasses impaired ETC
Magnesium (glycinate or malate) 400–800 mg elemental Divided doses, PM BH4_NOS (eNOS cofactor), TRPV1_SENSITIZATION NOS cofactor; NMDA modulation; reduces neurogenic pain spread
EPA/DHA (high-dose) 3–4 g combined EPA+DHA/day With fat TRANSMURAL_INFLAMMATION, ADIPOSE_INFLAMMATION_LOCK Resolvin/protectin precursors; IL-6/TNF-α suppression; membrane stabilization
Curcumin (with piperine or liposomal) 1–2 g/day With fat TRANSMURAL_INFLAMMATION, CYTOKINE_STORM_LOCK NFκB inhibition; Th17 suppression; JAK-STAT modulation
Rationale: ME/CFS mitochondrial failure is the energy bottleneck. Without ATP, immune cells cannot resolve inflammation, gut barrier cannot repair, and the brain cannot modulate pain. CoQ10 + ALA are non-negotiable for this patient.
Tier 4 — Immune Modulation (Start Day 60–75)
Supplement Dose Timing Target Shunt Mechanism
Vitamin D3 10,000–20,000 IU/day (target 25(OH)D >60 ng/mL) AM with fat VITAMIN_IMMUNE_LOCK, TH17_TREG_IMBALANCE_LOCK VDR activation → Treg promotion, Th17 suppression; reduces ACPA
Vitamin K2 (MK-7) 200–400 mcg/day With D3 + fat VITAMIN_IMMUNE_LOCK Calcium trafficking; vascular protection; osteocalcin activation
Epicatechin 200–400 mg/day With meals BH4_NOS eNOS Ser1177 phosphorylation → NO bioavailability; reduces oxidative stress
L-Citrulline 3–6 g/day Divided doses BH4_NOS Arginine recycling; preferential eNOS substrate; reduces ornithine/urea cycle stress
Rationale: Vitamin D is the master immune modulator in this case. The cholecystectomy caused fat-malabsorption → 25(OH)D3 <20. Without D3, Treg suppression fails and Th17 keeps driving RA + Crohn’s. K2 is required to prevent D3-induced vascular calcification (relevant with RA endothelial damage).
Tier 5 — Iron + B12 Repletion (Start Day 90–120, After JAK Inhibitor if Needed)
Supplement Dose Timing Target Shunt Mechanism
Iron bisglycinate (chelated) 25–50 mg elemental Away from other minerals, with vitamin C IRON_OVERUTILIZATION_LOCK, REDOX_ANTIOXIDANT Heme synthesis substrate; only after JAK inhibition or phlebotomy
Intrinsic factor + B12 1000 mcg B12 + IF complex Sublingual or with food BH4_NOS, BH4_AAAH Methylation restoration; homocysteine reduction → BH4 preservation
⚠️ CRITICAL: Iron repletion without JAK inhibition causes rebound (simulation showed load 0.800 → 1.000). The polycythemia JAK2 drive uses any available iron to surge RBC production. In this simulation, iron was added at day 120 but caused a bounce. Clinical sequence: Ruxolitinib → phlebotomy → THEN iron.
Tier 6 — Skin/Electrophile Defense (Start Day 0 for Active Dermatitis, Otherwise Day 60)
Supplement Dose Timing Target Shunt Mechanism
Quercetin (additional dose) +500 mg/day Divided doses MAST_CELL_DERMAL_BLISTERING_CASCADE Mast cell stabilization in dermis; inhibits histamine/tryptase release
Vitamin C (additional dose) +2 g/day (total 4–6 g) Divided doses ELECTROPHILE_NUCLEOPHILE_ADDUCTION Direct electrophile scavenging; collagen synthesis for wound repair
NAC (additional dose) +600–1200 mg/day (total 1800–3600 mg) With meals ELECTROPHILE_NUCLEOPHILE_ADDUCTION Sacrificial nucleophile pool for skin; raises epidermal GSH
Rationale: In this patient, systemic GSH depletion means skin has no reserve nucleophiles. Every MI/MCI or formaldehyde exposure causes direct protein haptenation. The extra NAC + vitamin C create a “thiol shield” that intercepts electrophiles before they bind BP180/desmoglein. Quercetin prevents the mast cell amplification that turns a small reaction into blistering.
External/Non-Supplement Interventions (Required)
Intervention Target Rationale
Ruxolitinib or Momelotinib (JAK1/2 inhibitor) JAK2_CONSTITUTIVE_ACTIVATION_LOCK Required before iron repletion. Without it, iron causes erythropoietic rebound.
Therapeutic phlebotomy VISCOSITY_HYPERCOAGULABILITY_LOCK Reduce Hct 45–55%. Each unit removes ~200 mg iron + reduces viscosity.
Hydroxyurea (alternative to JAK inhibitor) JAK2_CONSTITUTIVE_ACTIVATION_LOCK Cytoreductive; suppresses erythropoiesis if JAK inhibitor unavailable.
Complete avoidance of electrophilic soaps ELECTROPHILE_NUCLEOPHILE_ADDUCTION Zero MI/MCI, formaldehyde releasers, fragrance aldehydes, essential oils. Use plain glycerin soap or sulfonated surfactants only.
Daily Stack Summary (At Full Implementation)
Time Supplements
Morning (with breakfast) Sapropterin BH4, Methylcobalamin B12, Folinic acid, Vitamin D3 + K2, CoQ10, EPA/DHA, Curcumin, Epicatechin
Midday (with lunch) NAC, Vitamin C, Quercetin, Iron (if cleared), Saccharomyces boulardii
Afternoon Glycine, L-Glutamine, Magnesium (first dose)
Evening (with dinner) NAC, Vitamin C, Quercetin, Alpha-lipoic acid, Zinc, Curcumin
Bedtime Magnesium (second dose), Glycine (final dose)
Expected Timeline & Biomarker Targets
Week Expected Change Verification
2–4 Energy improvement, less brain fog Plasma glycine >200 µM, BH4/BH2 ratio >0.5
4–6 Gut symptoms improve, histamine reactions lessen Fecal calprotectin <250, plasma histamine <10 ng/mL 6–8 Skin reactivity decreases, fewer blisters Free thiols (skin) >60 µmol/g, serum tryptase <11.5
8–12 Joint pain reduction, HbA1c down CRP <5, IL-17A <10, HbA1c down 0.3–0.5%
12–16 Iron repletion tolerated (post-JAK inhibitor) Ferritin 50–100, TSAT 20–30%, no Hct rebound
6–12 months JAK inhibitor taper possible JAK2 V617F allele burden <10%, symptom stability
Red Flags — Stop/Adjust If
Symptom Interpretation Action
MCAS flare in weeks 2–4 DAO/HNMT reactivation but mast cells degranulating Add cromolyn sodium temporarily; slow NAC ramp
T2D worsens on glycine Glycine shunted to GSH, not reaching insulin signaling Add betaine (BHMT pathway) to spare glycine
Peroxynitrite surge despite BH4 NOS still uncoupled (ADMA high, BH4 oxidized faster than repleted) Add epicatechin + folate-5-MTHF aggressively
Iron repletion causes fatigue/pain return JAK2 rebound → viscosity ↑ → endothelial stress Stop iron. Start JAK inhibitor first.
Skin blistering on “natural” products Essential oils (citral, geraniol = aldehydes) are electrophiles Absolute avoidance of all fragrances, essential oils, MI/MCI, quaternium-15
Bottom Line
This patient’s stack requires 21+ active agents across 6 tiers. The non-negotiables are:
BH4 + glycine + NAC — the redox/methylation triad
Quercetin + vitamin C — mast cell and electrophile defense
JAK inhibitor + phlebotomy — required before iron; the simulation proves iron alone causes rebound
Total avoidance of electrophilic personal care products — the ContactAutoimmuneDermatitisProfile shows this is not optional; skin GSH is too depleted to intercept
The simulation predicts that with this full stack + JAK inhibition, the allostatic load can be driven from 0.83 to <0.5 within 6 months, and the BH4_NOS shunt can recouple (coupling ratio >0.5), releasing the peroxynitrite brake and allowing sequential decompression of the remaining locked pathways.
